Gilead targets durable autoimmune remission with $2.18bn Ouro Medicines acquisition
Gilead Sciences acquires Ouro Medicines for up to $2.18bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Analysis of what the deal reveals.
Pharma & Biotech